Looking into the seeds of time

Peanut allergy affects 1.4% to 4.5% of children and fewer than 25% are anticipated to outgrow peanut allergy naturally, with many sufferers having severe reactions.1–3 Although no approved therapy is currently available, 2 products are in phase III trials, and multiple centers and offices already engage in off-label clinical oral immunotherapy (OIT) programs.4 Such for-profit programs boast good success but, because of their "unregulated" status, data are sparse (or possibly not even collected), making it difficult to compare such programs with formally regulated and Good Clinical Practices–compliant clinical trials for OIT, despite it already being evident that more patients have undergone "off-label" OIT than have completed formal clinical trials.

https://ift.tt/2Fzowkn